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Objective: Recently there has been emerging clinical and research interest in the application of deep brain
stimulation (DBS) and repetitive transcranial magnetic stimulation (rTMS) to the treatment of anorexia nervosa (AN).
To our knowledge, few studies have discussed ethical aspects associated with the increased use of
neuromodulation in AN, some of which are quite specific to AN, despite the rapid development and dissemination
of these new technologies.
Method: We provide a brief overview of three published rTMS studies for AN and discuss ethical issues involved in
the use of neuromodulation for AN.
Results: In contrast to neurosurgery or DBS, rTMS is a less invasive technique, with less associated risk, and thus has
greater potential to become a more widespread augmentation or add-on therapy for AN. New therapeutic procedures
are promising, yet they raise ethical questions regarding informed consent and patient selection. Illness-specific issues
surrounding authenticity and autonomy are important to consider, ensuring an ethical approach to treatment for
patients with AN.
Discussion: We argue that ethical investigations for neuromodulation techniques are timely and important, and
discussions should go beyond the immediate goals of patient safety, consent, and risk and benefit, to consider broader
ethical concepts such as authenticity and autonomy.Review
Recently, the US National Institute of Mental Health
(NIMH) has moved towards a conceptualization of AN as
a disorder of neurocircuitry which can be elucidated with
modern tools and technological advances, especially gen-
omics and neuroimaging [1]. At present, the aetiology and
pathophysiology of AN are not completely known, yet
genetic and neuroimaging studies are revealing greater
insight into the underlying neural correlates which might
be involved in the aetiology of AN. To date, neuroimaging,
especially fMRI studies, suggest alterations in the dorsolat-
eral prefrontal cortex area (DLPFC), insular, parietal and
anterior cingulated cortex, all of which are areas involved
in emotional processing, processing of reward, and body
perception [2,3]. Traditionally, study paradigms used in* Correspondence: alina.coman@medisin.uio.no
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unless otherwise stated.neuroimaging have focused on investigating response to
food and body stimuli, and illness-specific brain activity
patterns related to symptoms. As has been acknowledged,
underweight status is an ever-present confounder in inves-
tigations of AN, and while some studies indicate the pres-
ence of pre-existing traits [4] other studies indicate the
existence of a scar effect due to underweight status or
malnutrition [5]. At present, knowledge about the rela-
tionship between brain activity and illness, as informed by
neuroimaging technologies, is correlational, yet findings
are typically used as a rationale for the application of neu-
romodulation techniques to the treatment of AN. Neuro-
modulation techniques include invasive methods such as
neurosurgery or deep brain stimulation (DBS), or non-
invasive brain stimulation (NIBS), including repetitive
transcranial stimulation (rTMS). Neuroimaging is seen as
a promising tool to improve the efficacy of these tech-
niques, especially rTMS by helping identify an appropriate
stimulation target, which is considered to be a current
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for treating psychiatric disorders in general is accumu-
lating, with a growing consensus towards the application of
neuromodulation such as rTMS in treating depression, for
example [7]. The invasive nature of these interventions, es-
pecially neurosurgery and DBS, and the inherent ethical
considerations render these forms of treatment a last-
resort for a subgroup of treatment-resistant patients. An-
orexia nervosa is associated with high mortality rates [8]
and a subgroup of patients experiences a chronic outcome
[9]. As such, neuromodulation techniques have been in-
creasingly proposed for the treatment of severe and long-
standing AN proven refractory to standard treatment [10].
Such neuromodulation techniques are often not stand-
alone treatment but they are used as additional or augmen-
tation treatment in combination with behavioural training
or other forms of therapy [11].
Some studies have shown positive results and provide
proof-of-concept for AN as a disorder of brain circuitry,
yet the mechanisms underlying neuromodulation tech-
niques are not completely known. For AN, the evidence
base for rTMS and DBS remains limited. Lipsman et al.
[12] offer a thorough historical overview of the literature
on the frequency and effects of neurosurgery. The lack of
understanding neurocircuitry and the lack of specificity in
targets of stimulation has made some critics advocate for
‘neuromodesty’ [13] and emphasize the necessity to inves-
tigate ethical aspects associated with neuromodulation.
History has shown that it is important to stay vigilant and
prevent misuse of these techniques in order to avoid nega-
tive experiences and attitudes that could deprive patients
of therapeutic help [6].
We feel that rapid advances and new research priorities
have arguably introduced a paradigm shift in defining and
treating AN, making a renewed discussion of associated
ethical concerns timely and important [11,12,14]. Some
have argued that elucidating important ethical concerns is
vital, especially since new technologies are often approved
and implemented without critical appraisal [15] and the
promise of neuroscience might, for some, have a “seduc-
tive” allure [16]. This appears to be also the case for psy-
chotropic medication that is still recommended to a group
of patients with AN despite known adverse effects and
lack of data supporting their efficacy [17].
Brain-based interventions, even neurosurgery for AN,
are not new [18]. Some have argued that although tech-
niques such as DBS or rTMS represent recent therapeutic
advances, the relevant ethical challenges they pose have
been previously addressed in the bioethical literature for
other medical or psychological treatments [13]. However,
whereas specific ethical issues related to DBS have been
discussed more broadly for other psychiatric disorders
[19-21], and recently for AN [22], few debates have fo-
cused on rTMS. Further, existing ethical evaluations ofrTMS for other psychiatric disorders have focused pre-
dominantly on safety issues alone [6].
This article can be seen as a first step in the endeavor to
shed light on specific ethical issues that the use of neuro-
modulation techniques pose for patients suffering from
AN. Although some issues pertain to neuromodulation
techniques at-large, we focus mainly on rTMS. Clinically
speaking, we feel a focus on rTMS is timely and import-
ant, as this procedure is less invasive and might be applied
less severe patients, thereby not constituting a ‘last-resort’
treatment, but possibly functioning as an additional or
augmentation treatment which is more widely accessible
to treatment providers. In contrast, DBS is a more invasive
treatment with greater challenges to issues of safety, long-
term effects and informed consent, and its use will most
probably be guided by restrictive regulations.
Neuromodulation techniques for AN: rTMS studies
Repetitive transcranial magnetic stimulation induces re-
petitive stimulation to cortical tissue with the help of mag-
netic field pulses from a magnetic coil placed outside the
head. It either suppresses (at low frequency, 1 Hz) or ex-
cites (at higher frequency, 20 Hz) cortical activity, and its
effect can propagate beyond the site of stimulation to a
network of brain regions. The only Food and Drug Ad-
ministration (FDA) approved therapeutic use of TMS
is for stimulating the dorsolateral prefrontal cortex
(DLPFC) for medication-resistant depression. However,
the therapeutic efficacy data for depression is limited,
partly because stimulation of DLPFC is based on a
vague understanding of which specific mechanisms are
stimulated, considering that DLPFC is connected with
many other brain areas [23].
There are six studies that explore the effects of rTMS
on bulimic disorders and findings are inconsistent, with
some studies showing placebo effects while other
reporting significant changes [10]. Three studies, of which
one is a single case study, explore effects of rTMS for
symptoms of AN. Table 1 provides a brief overview of
clinical details and outcome for the three studies for AN.
Initial findings are promising, yet mixed [24-26]. No stud-
ies have yet assessed the duration of improvement in
symptoms beyond one month, or the longer-term and sec-
ondary effects of these interventions, and future studies
will need to establish for which patients these interven-
tions work best. Randomized controlled studies, which are
underway in several countries including the UK and
France, are necessary to delineate specific effects of rTMS
and confirm the proof-of-concept for rTMS as a method
which affects disturbed neural circuitry for reward and
self-regulation [25]. Thus far, however, the use of these
methods is exploratory and mostly confined to research
settings and has not been routinely implemented as a
therapeutic technique in the clinics.
Table 1 rTMS studies in anorexia nervosa
Authors (year) N Patient characteristics Treatment Primary outcome
Kamolz et al. (2008) [24] 1 Gender: female Treatment of comorbid depression in a female patient with AN. Improvement in depression was observed, as well as weight
gain and fewer ED symptoms. After 1st cycle, HAM-D scores
decreased from 28 to 14. After 2nd cycle, HAM-D scores
decreased from 18 to 10. After 3rd cycle, HAM-D scores
decreased 18 to 11. During continuation therapy, HAM-D
scores remained between 8 and 10.
Age: 24 yrs.
BMI: 12.4 1st cycle included 10 sessions within 16 days of
high frequency rTMS to the left dorsolateral
prefrontal cortex. 2nd cycle included 6 sessions.
3rd cycle included 10 sessions.
DOI: app. 4 yrs.
Continuation therapy included twice weekly
rTMS sessions for 8 weeks.
BMI increased to approximately 16 kg/m2 after 12 weeks of rTMS.
Van den Eynde et al. (2013) [25] 10 Gender: female Delivered 1 session of high frequency rTMS to
the left dorsolateral prefrontal cortex.
1 patient dropped out prematurely due to discomfort.
Mean age: 25 yrs. On the visual analogue scale, significant reductions in feeling fat,
feeling full, and anxiety, with a non-significant trend for
decreased urge to exercise. No significant changes in mood,
tension, hunger, “urge to eat” or “urge to restrict”. No reduction
in cortisol levels, but found to be cardiac safe, as measured
by blood pressure and heart rate.
ED-related experiences were measured pre-post
following exposure to visual and food stimuli(18-44)
Mean BMI: 15.7
(13.8-17.8)
DOI: 10 yrs (3–30)
McClelland et al. (2013) [26] 2 Patient A Delivered 19–20 sessions of high frequency rTMS,
applied to the left dorsolateral prefrontal cortex.
Patient A
Gender: female No change in weight at post-treatment or at 1-month follow-up.
EDE-Q scores (except Eating Concern) were significantly lower at
post-treatment and improvements were maintained at FUP.
Some improvement in depression was observed.
Age: 23 yrs.
BMI: 15.7 Within-session changes in ED-related experiences were
measured. BMI, ED symptoms, and depression measured
at pre-treatment, post-treatment, and 1-month follow-up.DOI: 12 yrs.
Patient B
Gender: female Patient B
No change in weight at post-treatment or 1-month
follow-up. Improvements in EDE-Q scores and
depression were observed.
Age: 52
BMI: 16.4
DOI: 35 yrs.
Note: rTMS = repetitive transcranial magnetic stimulation; BMI = body mass index (kg/m2); DOI = duration of illness; HAM-D = Hamilton Depression Scale; EDE-Q = Eating Disorder Examination-Questionnaire,
FUP = follow-up period.
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In the treatment of AN, ethical discussions have mostly
focused on clinical issues related to underweight, malnu-
trition, and the capacity to refuse treatment. However,
with the increased use of brain interventions for treating
AN, other ethical concerns specific to the application of
(mechanical) brain interventions need elaboration.
Ethical assessment of the use of neuromodulation is
often based on four principles: respect for autonomy,
beneficence, non-maleficence, and justice. Table 2 pro-
vides an overview of the application of these ethical
principles to the case of rTMS in AN. The following sec-
tion summarizes and relates these aspects to principal-
ism, as this is the most influential approach in bioethics.
Balancing non-maleficence and beneficence
So far, the risks associated with participating in rTMS are
low; however, since there is no evidence for the long-term
effects and efficacy of rTMS, the risk-benefit ratio is diffi-
cult to assess [21]. Hence, utilitarian analysis fails to provide
clear guidance in decision-making, and the beneficence is
unclear. A pilot study for rTMS showed reductions in feel-
ing of fatness and fullness, and anxiety, but fewer changes
in mood, tension or urge to exercise [25]. In the future, it
will also be relevant to establish criteria for evaluating ef-
fectiveness. If rTMS is proven effective and alleviates symp-
toms, it is relevant to establish the criteria for patient
inclusion that should be adopted before neuromodulation
is recommended, and establish the patient group for whom
rTMS is relevant. In Van den Eynde’s study [25], the group
of participants investigated was heterogeneous, and in-
cluded individuals with different duration of disorders,
which make it hard to know whether neuromodulatory in-
terventions are more effective for less severe patients or
chronic patients. Difficulties and disagreement over the
definition of severity, e.g., in terms of BMI-alone, level of
impairment, or other eating-related or general psycho-
pathology, has thus far rendered the assessment of benefi-
cence complicated.Table 2 rTMS in AN and relevant ethical considerations
Ethical principle Threats pertinent for rTMS in AN
Non-maleficence (do no harm) Risks
Side-effects and long-term effects
Beneficence (do well) Effectiveness
Patient selection
Respect for autonomy Informed consent
(Emotional and cognitive) capacity
issue due to underweight
Comorbidity, mortality,
resistance to treatment
Justice Patient selection, Resource allocation,
Research deprivationRelated to this argument, illness duration and refrac-
toriness to treatment is often invoked as a rationale for
neuromodulation [12]. Some have argued that moderate
or a less severe illness might in fact be more responsive
to brain interventions [27]. In AN, chronicity is typically
seen after a period of 10 years [28]. Treating only pa-
tients with a long duration of illness may do injustice to
individuals with a shorter duration of illness [27]. Thus
ensuring a favorable risk-benefit ratio has also a moral
aspect where issues of safety have to be balanced with
the desire to help a group of patients who are not helped
by other methods. This poses problems for autonomy
and informed consent.
Respect for autonomy
Respect for autonomy is usually ensured by proper in-
formed consent. At present, rTMS (and DBS) interven-
tions for AN are often a last–resort treatment for patients
who do not respond to other treatments. It has often been
underlined in the ethics literature that patients participat-
ing in such last-resort exploratory research or treatment
trials are “desperate” for a solution. As such, this subgroup
of treatment refractory patients may be “overly motivated’
to participate in exploratory research and to expose them-
selves to risks [13]. This poses challenges to the capacity
of these patients to fully understand the nature of inter-
vention and implications of participation. Depression can
affect perception of risks associated with participating in
research [19], although some argue that depression in it-
self is not enough to compromise judgment [29]. For AN,
the condition of severe underweight poses some additional
ethical considerations of competency and non-maleficence.
Severe underweight can lead to involuntary hospitalization
and forced feeding based on the assumption that individ-
uals lack cognitive or emotional capacity to make decisions
[30]. Offering neuromodulation treatment to patients who
are emaciated or malnourished poses inherent ethical di-
lemmas given the potential incapacity associated with
underweight status.
While some rTMS studies conducted so far have ex-
cluded severely underweight patients, protecting them from
harm, other studies have included patients with a BMI from
12.3.
Chronicity of illness, underweight and willingness to
participate in last resort interventions, be it proven or ex-
perimental, can raise questions about the validity of in-
formed consent. The validity of a consent coming from a
person that is severely underweight, refractory to treat-
ment, yet willing to undergo brain interventions, can be
questioned. Assessing the validity of such consent will be
dependent on objective and established criteria for compe-
tence. However, it is also dependant on the kind of policy
adopted, either a restrictive, paternalistic attitude or a per-
missive one “permitting people to make unencumbered
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how low the competence bar is set [13]. In cases where
the competence bar is set low, it is essential to disclose to
the participant all known and unknown information about
the intervention in order to ensure informed consent.
The “overtly motivated,” possibly depressed patient is
a general ethical concern. However, in AN, a lack of mo-
tivation and reluctance to engage in treatment has more
often been the case. Especially pharmacological treat-
ment, for example, antipsychotic medication such as
olanzapine, is associated with higher drop-out than cog-
nitive [31] and cognitive-behavioural treatment [32].
Further, the drop-out rate for adults with AN is higher
(40%) than for adolescents in family therapy, in which
the drop-out rates fall around 10-20% [32]. However, re-
luctance to medication might be explained by fears of
weight gain, which can be a secondary effect of olanza-
pine [33]. Although it remains yet unknown how pa-
tients view neuromodulatory treatments, rTMS has been
shown to reduce feelings of fullness or fatness, and to
lessen anxiety, which may have greater appeal. In this
case, the concern is rather, when the patient is moti-
vated, how to proceed ethically. Given the current lim-
ited status of knowledge of neurocorrelates for AN, of
the efficacy of mechanisms for brain stimulation and
long-term effects, critics have drawn attention to the fact
that neuromodulation means little. To proceed ethically
would mean an invitation to “hyper disclosure” [13].
Another threat to autonomous participation in neuromo-
dulatory interventions is the risk for therapeutic misconcep-
tion, adopting the belief that participating in research will
alleviate suffering. Informed consent should therefore aim
to avoid misunderstanding, and facilitate autonomy, by
making explicit the current experimental nature of the re-
search, and ensure that the patient is explicitly informed
about what rTMS can offer and not offer.
It is also possible that investigator bias, or simply the
desire to understand the relation between the brain and
illness, or to alleviate intense suffering, leads to over-
statements of the current state of knowledge and this
can impede cautious proceeding [13]. Especially in light
of the high mortality and morbidity rate, AN may chal-
lenge the therapists’ clinical judgment and bias them to
recommend the available new treatments, despite an
evidence base which is still evolving. On the other hand,
any negative attitudes or bias against brain interven-
tions may encourage therapists to withhold treatment
from patients [6].
Justice
Critics have drawn attention to the need to balance eth-
ical concerns and (over) protection of rights that has
sometimes led to “research deprivation” [34]. This is per-
haps especially applicable to children and adolescentswith AN, with a consideration of young individuals’
agency [35] and the need to proceed cautiously.
Researchers have already pointed to the perplexities of
providing sound scientific evidence for medicated treat-
ment and how consideration for safety by including the
adult population entails high drop-out and biases sam-
ples [32]. This has made researchers inclined to advocate
intensification of interventions at early stages of the dis-
order instead of conducting more randomized studies
[32]. Others have warranted a more detailed and critical
re-evaluation of the meaning and criteria for resistance
to treatment [36], as it is an often-invoked argument for
use of neuromodulation techniques but little described
in the studies [12].
Autonomy and beyond: authenticity
Whether such interventions are proven effective in the fu-
ture and the medical risks low, it will still be necessary to
provide adequate care and attention to the individual and
also longer-term follow-up. Resistance to standard treat-
ment is often invoked by patients on the grounds of
threats to authenticity, where aspects of AN are seen as
integrative of the self and therefore the patient is less will-
ing to change [37]. All treatments, medical or psycho-
logical, can be said to change aspects of the self, and to
either threaten or contribute to the development of what
is conceived as “authentic”, although this concept is con-
tested [38]. Although the understanding of authenticity
and the role of this concept in treatment is still poorly
understood, studies show that threats to authenticity are
experienced by patients although mostly in the beginning
of the treatment as grounds to refuse treatment [37]. Al-
though concerns for authenticity appear to be amenable
to change over time, and should not just be taken at face-
value as a valid reason to respect patients’ refusal of treat-
ment, an ethical approach to treatment requires neverthe-
less a consideration of patients’ concerns with authenticity.
Technological assisted treatment, as with rTMS, touches
on broader debates about the nature and meaning of
symptoms and neuromodulatory techniques. As men-
tioned earlier, the results from early trials of rTMS seem
to show reductions in feelings of fullness and fatness. Yet
patients may be reluctant to address ideas regarding over-
concern of shape and weight, which may be intertwined
with the subjective meaning of the illness ascribed by the
patient [39]. For example, feelings of fatness have been
shown to be related to expressing emotions of sadness or
disgust that are displaced on the body, and depend on
context [40]. Preoccupation with the body, restriction,
purging can be seen as concrete representation of psycho-
logical states, a tendency some have termed ‘psychological
equivalence’ [41].
Importantly, differentiating between the meaning of
symptoms according to the patient and the aetiology of
Coman et al. Journal of Eating Disorders 2014, 2:10 Page 6 of 7
http://www.jeatdisord.com/content/2/1/10symptoms demands clinical skills from the therapists. It
is feasible that recommending a neuromodulation tech-
nique might alienate the patient by rendering important
and ego-syntonic symptoms reducible to defect neuro-
networks. Earlier studies show that although biological
framing of the disorder can reduce self-blame, it can also
disturb self-understanding and the perception of volition
seen as significant for recovery [42,43]. Therefore the
therapist is in a position to address participants concerns
about authenticity and agency when they jointly deter-
mine treatment goals [37].
A complementary criterion: individual experience, cultural
and social aspects.
The risk-benefit calculations must be based on assessing
effectiveness both at the group level but also at the individ-
ual level [44]. At present, it remains uncertain how patients
might experience these technologies and whether they
present threats to authenticity. We argue that this should be
done not only based on quantitative measures of benefit,
but should be complemented by a first-person account of
the role such technologies play in the life of the sufferer. For
example, such first-person accounts have been shown to be
a contribution to the debate about medication of children
with ADHD [38]. The answers to these questions could
ensure a complete ethical evaluation and ethical approach to
the use of neurotechnologies, and prevent “clinical push”
and technological enthusiasm which may create stigma that
would deprive sufferers of therapeutic benefit [6].
Lastly, ethical perspectives may be influenced by cultural
and societal values. While the media is increasingly pre-
senting the brain as a “capital that should be optimized”
[45], and the brain becomes an integrated, although not
dominant part of our self-understanding [43,46], the pub-
lic may become more cautious about brain interventions
as neuromodulation techniques have a controversial his-
tory [6]. Such social and cultural values might also be im-
pacted by the specific features of the disorder, and
attention to context is warranted [13]. Limited knowledge
exists regarding factors, which might impede or encourage
acceptability of neuromodulation interventions for both
sufferers, health professionals and the general public [14].
Conclusions
This article can be seen as a first step in the attempt to shed
light on specific ethical issues that the use of neuromodula-
tion techniques pose for patients with AN. Although prom-
ising, findings are mixed and future studies are warranted
to demonstrate their efficacy. The risks for rTMS are cur-
rently low and thus further experimental trials can proceed
and ensure consistent evidence for the efficacy of the neu-
romodulation techniques. However, considering the current
limited knowledge, careful attention to context and practice
should follow. Ethical issues such as careful informedconsent and clinical sensitivity have to be taken into ac-
count when gaining this knowledge and applying these
techniques. Further, if these methods prove effective, it is
nevertheless relevant that patients, families, caregivers,
treatment providers, and the public-at-large are involved in
discussions regarding potential ethical dilemmas.
In this article, we have applied a principle-based approach
as described by Beauchamp and Childress [47]. Other per-
spectives exist and could have been followed; for example, a
deontological approach would have highlighted human
worth and dignity. However, our approach addressed con-
cerns for authenticity and meaning without reference to
intention-based ethical theories. The utilitarian perspective
has been covered by the principle of beneficence. Various
types of utilitarianism exist, but they are all faced with chal-
lenges when the knowledge on risks and benefits is vague,
uncertain, or absent. Correspondingly, procedural ap-
proaches, such as discourse ethics [48] and “accountability
for reasonableness” [49,50] are relevant, especially when
assessing health care interventions under uncertainty. How-
ever, they may face challenges in AN as the persons them-
selves may refuse to be participants in the discourse and
deliberation.
In conclusion, we argue that investigations of neurosti-
mulation techniques such as rTMS in AN go beyond estab-
lishing efficacy to a broader phenomenological, first-person
understanding of how technologies affect users’ lives. As
such, future studies and ethical debates about the efficacy
and acceptability of these methods should therefore investi-
gate attitudes both among health providers and patients. Fi-
nally, considering that research on neurobiology of AN will
most likely continue to rapidly develop in concert with
NIMH research priorities, concomitant ethical debates
should follow in parallel with such developments.
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